Triple GLP-1/GIP/glucagon receptor agonist with superior weight loss effects compared to semaglutide and tirzepatide
Recommended Dosage: 0.5-12 mg weekly, gradually titrated based on tolerance
Typical Duration: Long-term therapy with medical supervision
Experimental compound in clinical trials. Requires medical supervision. Monitor for GI side effects and gradual dose escalation.
Storage: Refrigerate at 2-8°C, do not freeze
If the information isn't correct, please type in the name of the peptide on PubMed to find accurate studies.